The effect of Ulinastatin on the inflammation response, pain, functional recovery after lower extremity ischemia-reperfusion injury

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-11001473

Enrollment

Unknown

Registered

2011-08-14

Start date

2011-09-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

total knee replacement

Interventions

1:Tianpuluoan, Ulinastatin, 10000u/kg, iv. after induction

2:Same volume of normal saline, iv, after induction.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: elective TKR, ASA 1-2, inflation tourniquets are used.

Exclusion criteria

Exclusion criteria: Rheumatic arthritis, severe hepatic and renal dysfunction, allergic to ulinastatin, on NSAIDS, anti-oxygenatives and/or vitamins, tourniquet time less than 60 minutes or more than 90 minutes.

Design outcomes

Primary

Measure	Time frame
inflammation factors;intraoperative hemodynamic, blood loss, adverse effect;knee joint function;	—

Secondary

Measure	Time frame
pain scale;	—

Countries

China

Contacts

Public ContactYuguang Huang

pumchhyg@yahoo.com.cn+86 010 65295580

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026